| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17160 R71968 |
Vaclavik - ACEs/ARBs, 2024 | Caesarean section | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 2.03 [1.61;2.56] | -/117 -/252,856 | - | 117 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17123 R71693 |
Van der Zande - ACE-Is and/or ARBs, 2024 | Caesarean section | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) Renin angiotensin: ARBs and/or ACEIs (Angiotensin II receptor blockers and/or Angiotensin-converting enzyme inhibitors) | 1.86 [1.00;3.48] C | 26/42 2,655/5,697 | 2,681 | 42 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14147 R55485 |
Hoeltzenbein a - ARBs, 2018 | C-section | early pregnancy excluded | prospective cohort | unexposed, disease free | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication Matched Renin angiotensin: ARBs (Angiotensin II receptor blockers) |
2.26 [1.59;3.22] C excluded (exposition period) |
88/162 193/560 | 281 | 162 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14211 R55714 |
Colvin - ACEi, 2014 | Caesarean | 1st trimester excluded | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified Renin angiotensin: ACEIs (Angiotensin-converting enzyme inhibitors) |
1.77 [0.93;3.37] excluded (exposition period) |
43/83 30,737/95,926 | 30,780 | 83 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14158 R55562 |
Moretti - ACEi/ARBs, 2012 | Cesarean section | 1st trimester excluded | prospective cohort | unexposed, disease free | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched Renin angiotensin: ARBs and/or ACEIs (Angiotensin II receptor blockers and/or Angiotensin-converting enzyme inhibitors) |
1.66 [0.97;2.87] C excluded (exposition period) |
46/108 37/120 | 83 | 108 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 2.01 [1.62;2.50] | 2,681 | 159 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded